RBC Capital Maintains Sector Perform on Bicycle Therapeutics, Lowers Price Target to $7

Benzinga Newsdesk www.benzinga.com Negative 70.7%

Neg 70.7% Neu 0% Pos 0%

RBC Capital analyst Leonid Timashev maintains Bicycle Therapeutics (NASDAQ:BCYC) with a Sector Perform and lowers the price target from $11 to $7.